Oral MGB-BP-3 has completed all preclinical and Phase I safety studies. The compound was formally selected as a candidate for clinical testing from a number of very promising lead molecules, demonstrating potent and rapid activity against a range of Gram-positive bacteria including MRSA, VRE, Streptococcus spp. and Clostridium difficile.
- Completion of Phase IIa clinical proof of concept studies with oral MGB-BP-3 for the eradication of Clostridium difficile-associated diarrhoea (CDAD)
- Completion of preclinical assessment of intravenous MGB-BP-3 for the treatment of systemic Gram-positive infections such as MRSA, VRE and Streptococcal infections
- Completion of preclinical topical MGB-BP-3 feasibility for the treatment of resistant skin infections
In addition to MGB-BP-3, there are further subfamilies of antibacterial compounds which have specific Gram-negative activity. These are being explored further in research collaboration with the University of Strathclyde, and a viable project plan now exists to move multiple compounds from hit to lead for this high medical need sector.
Within the MGB Biopharma patent estate, there is a further set of distinctive chemical subfamilies. Although these are not effective against bacteria, they do possess specific anti-fungal, anti-parasitic and anti-viral properties. The company is exploring collaborations to advance these programmes.
Anti-viral possibilities: The MGB platform contains compounds with activity against viruses, such as Hepatitis.